Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
Nick Clegg will attempt to win over the female electorate when he kicks off the Liberal Democrats' general election campaign later today.
Up to £140 billion of savings could be released when over 55-year-olds are allowed to cash in their pension pots from April 6th.
The party's plans include a £2.5 billion Time to Care fund for the NHS, capping rail fare increases and 3,000 more midwives.